Margret Jandl

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 168 citations · Full text

Asthma, Severe Eosinophilic Asthma, Allergy +10

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling et al. · The Lancet Respiratory Medicine · 2023 · 127 citations · Full text

Asthma, Rheumatology, Allergy +9

Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study

David J. Jackson, Liam G. Heaney, Marc Humbert et al. · The Lancet · 2023 · 116 citations · Full text

<p>Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)</p>

Reynold A. Panettieri, Tobias Welte, Kartik Shenoy et al. · Journal of Asthma and Allergy · 2020 · 41 citations · Full text

Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial

Fernando J. Martínez, Gerard J. Criner, Margret Jandl et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 41 citations · Full text